Download PDF
Semin Liver Dis 2008; 28(2): 210-217
DOI: 10.1055/s-2008-1073120
© Thieme Medical Publishers

Artificial and Bioartificial Liver Support

Travis J. McKenzie1 , Joseph B. Lillegard1 , Scott L. Nyberg1
  • 1Department of Surgery, Mayo Clinic, Rochester, Minnesota
Further Information

Publication History

Publication Date:
02 May 2008 (online)

    Permissions and Reprints

ABSTRACT

Acute liver failure (ALF) is a widespread problem with an unfavorable prognosis. Currently, liver transplantation is the only direct means of treatment for patients in ALF. Due to the scarcity of donor organs, liver support technologies are being developed and clinically tested with the intent of supporting a patient in ALF until the patient regains native liver function or until a donor organ becomes available. Two major categories of devices are currently being tested. Artificial liver support is purely mechanical, including albumin dialysis. Bioartificial devices contain cellular material. No single system has reproducibly demonstrated improvement in patient mortality. However, with the advent of new technology and cell acquisition techniques, further randomized controlled trials will be necessary to determine the role of artificial and bioartificial liver support devices in the treatment of patients with ALF.

KEYWORDS

Acute liver failure - bioartificial liver - artificial liver - liver support device

REFERENCES

  • 1 Khashab M, Tector A J, Kwo P Y. Epidemiology of acute liver failure.  Curr Gastroenterol Rep. 2007;  9 66-73
    CrossrefPubMedGoogle Scholar
  • 2 Ostapowicz G, Fontana R J, Schiødt F V et al.. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States.  Ann Intern Med. 2002;  137 947-954
    CrossrefPubMedGoogle Scholar
  • 3 Farges O, Kalil A N, Samuel D et al.. The use of ABO-incompatible grafts in liver transplantation: a life-saving procedure in highly selected patients.  Transplantation. 1995;  59 1124-1133
    PubMedGoogle Scholar
  • 4 Sorrentino F. Prime ricerche per la realizzatione di un fegato artificiale.  Chir Patol Sper. 1956;  4 1401
    PubMedGoogle Scholar
  • 5 Stange J, Ramlow W, Mitzner S, Schmidt R, Klinkmann H. Dialysis against a recycled albumin solution enables the removal of albumin bound toxins.  Artif Organs. 1993;  17 809-813
    CrossrefPubMedGoogle Scholar
  • 6 Stange J, Mitzner S, Risler T et al.. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support.  Artif Organs. 1999;  23 319-330
    PubMedGoogle Scholar
  • 7 Steiner C, Sen S, Stange J, Williams R, Jalan R. Binding of bilirubin and bromosulphthalein to albumin: implications for understanding the pathophysiology of liver failure and its management.  Liver Transpl. 2004;  10 1531-1538
    CrossrefPubMedGoogle Scholar
  • 8 Awad S S, Swaniker F, Magee J, Punch J, Bartlett R H. Results of a phase I trial evaluating a liver support device utilizing albumin dialysis.  Surgery. 2001;  130 354-362
    CrossrefPubMedGoogle Scholar
  • 9 Khuroo M S, Khuroo M S, Farahat K L. Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis.  Liver Transpl. 2004;  10 1099-1106
    CrossrefPubMedGoogle Scholar
  • 10 Novelli G, Rossi M, Pugliese F et al.. Molecular adsorbents recirculating system treatment in acute-on-chronic hepatitis patients on the transplant waiting list improves model for end-stage liver disease scores.  Transplant Proc. 2007;  39 1864-1867
    CrossrefPubMedGoogle Scholar
  • 11 Falkenhagen D, Strobl W, Vogt G et al.. Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances.  Artif Organs. 1999;  23 81-86
    CrossrefPubMedGoogle Scholar
  • 12 Santoro A, Faenza S, Mancini E et al.. Prometheus system: a technological support in liver failure.  Transplant Proc. 2006;  38 1078-1082
    CrossrefPubMedGoogle Scholar
  • 13 Rifai K, Ernst T, Kretschmer U et al.. Prometheus: a new extracorporeal system for the treatment of liver failure.  J Hepatol. 2003;  39 984-990
    CrossrefPubMedGoogle Scholar
  • 14 Herget-Rosenthal S. Citrate anticoagulated modified fractionated plasma separation and adsorption: first clinical efficacy and safety data in liver failure.  J Am Soc Nephrol. 2003;  14 729A
    PubMedGoogle Scholar
  • 15 Kramer L. Clinical experience with artifical liver support in chronic liver failure with encephalopathy [abstract].  ASAIO J. 2000;  a211
    PubMedGoogle Scholar
  • 16 Evenepoel P, Laleman W, Wilmer A et al.. Prometheus versus molecular adsorbents recirculating system: comparison of efficiency in two different liver detoxification devices.  Artif Organs. 2006;  30 276-284
    CrossrefPubMedGoogle Scholar
  • 17 Sussman N L, Kelly J H. Extracorporeal liver support: cell-based therapy for the failing liver.  Am J Kidney Dis. 1997;  30(suppl 4) S66-S71
    CrossrefPubMedGoogle Scholar
  • 18 Allen J W, Hassanein T, Bhatia S N. Advances in bioartificial liver devices.  Hepatology. 2001;  34 447-455
    CrossrefPubMedGoogle Scholar
  • 19 Spray D C, Fujita M, Saez J C et al.. Proteoglycans and glycosaminoglycans induce gap junction synthesis and function in primary liver cultures.  J Cell Biol. 1987;  105 541-551
    CrossrefPubMedGoogle Scholar
  • 20 Yarmush M L, Dunn J C, Tompkins R G. Assessment of artificial liver support technology.  Cell Transplant. 1992;  1 323-341
    PubMedGoogle Scholar
  • 21 Ellis A J, Hughes R D, Nicholl D et al.. Temporary extracorporeal liver support for severe acute alcoholic hepatitis using BioLogic-DT.  Int J Artif Organs. 1999;  22 27-34
    PubMedGoogle Scholar
  • 22 Nyberg S L, Remmel R P, Mann H J et al.. Primary hepatocytes outperform Hep G2 cells as the source of biotransformation functions in a bioartificial liver.  Ann Surg. 1994;  220 59-67
    PubMedGoogle Scholar
  • 23 Ellis A J, Sussman N L, Kelly J H, Williams R. Clinical experience with an extracorporeal liver assist device. In: Lee W, Williams R Acute Liver Failure. Cambridge; Cambridge University Press 1997: 255-265
    Google Scholar
  • 24 Mavri-Damelin D, Damelin L H, Eaton S et al.. Cells for bioartificial liver devices: the human hepatoma-derived cell line C3A produces urea but does not detoxify ammonia.  Biotechnol Bioeng. 2008;  99 644-651
    PubMedGoogle Scholar
  • 25 Ellis A J, Hughes R D, Wendon J et al.. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure.  Hepatology. 1996;  24 1446-1451
    CrossrefPubMedGoogle Scholar
  • 26 Patience C, Takeuchi Y, Weiss R A. Infection of human cells by an endogenous retrovirus of pigs.  Nat Med. 1997;  3 282-286
    CrossrefPubMedGoogle Scholar
  • 27 Sussman N L, Gislason G T, Conlin C A, Kelly J H. The Hepatix extracorporeal liver assist device: initial clinical experience.  Artif Organs. 1994;  18 390-396
    PubMedGoogle Scholar
  • 28 Patience C, Patton G S, Takeuchi Y et al.. No evidence of pig DNA or retroviral infection in patients with short-term extracorporeal connection to pig kidneys.  Lancet. 1998;  352 699-701
    CrossrefPubMedGoogle Scholar
  • 29 Paradis K, Langford G, Long Z et al.. Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue.  Science. 1999;  285 1236-1241
    CrossrefPubMedGoogle Scholar
  • 30 Pitkin Z, Switzer W, Chapman L. An interim analysis of PERV infectivity in 74 patients treated with a bioartificial liver in a prospective, randomized, multicenter controlled trial.  Hepatology. 2001;  34 249A
    CrossrefPubMedGoogle Scholar
  • 31 Watanabe F D, Mullon C J, Hewitt W R et al.. Clinical experience with a bioartificial liver in the treatment of severe liver failure: a phase I clinical trial.  Ann Surg. 1997;  225 484-491
    CrossrefPubMedGoogle Scholar
  • 32 Demetriou A A, Brown Jr R S, Busuttil R W et al.. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure.  Ann Surg. 2004;  239 660-667
    CrossrefPubMedGoogle Scholar
  • 33 Sauer I M, Kardassis D, Zeillinger K et al.. Clinical extracorporeal hybrid liver support: phase I study with primary porcine liver cells.  Xenotransplantation. 2003;  10 460-469
    CrossrefPubMedGoogle Scholar
  • 34 Mazariegos G V, Kramer D J, Lopez R C et al.. Safety observations in phase I clinical evaluation of the Excorp Medical bioartificial liver support system after the first four patients.  ASAIO J. 2001;  47 471-475
    CrossrefPubMedGoogle Scholar
  • 35 Van De Kerkhove M P, Di Florio E, Scuderi V et al.. Phase I clinical trial with the AMC-bioartificial liver.  Int J Artif Organs. 2002;  25 950-959
    PubMedGoogle Scholar
  • 36 Uchino J, Tsuburaya T, Kumagai F et al.. A hybrid bioartificial liver composed of multiplated hepatocyte monolayers.  ASAIO Trans. 1988;  34 972-977
    PubMedGoogle Scholar
  • 37 Margulis M S, Erukhimov E A, Andreiman L A, Viksna L M. Temporary organ substitution by hemoperfusion through suspension of active donor hepatocytes in a total complex of intensive therapy in patients with acute hepatic insufficiency.  Resuscitation. 1989;  18 85-94
    CrossrefPubMedGoogle Scholar
  • 38 Matsumura K N, Guevara G R, Huston H et al.. Hybrid bioartificial liver in hepatic failure: preliminary clinical report.  Surgery. 1987;  101 99-103
    PubMedGoogle Scholar
  • 39 Matsushita T, Amiot B, Hardin J, Platt J L, Nyberg S L. Membrane pore size impacts performance of a xenogeneic bioartificial liver.  Transplantation. 2003;  76 1299-1305
    CrossrefPubMedGoogle Scholar
  • 40 Nyberg S L, Hardin J, Amiot B et al.. Rapid, large-scale formation of porcine hepatocyte spheroids in a novel spheroid reservoir bioartificial liver.  Liver Transpl. 2005;  11 901-910
    CrossrefPubMedGoogle Scholar
  • 41 Cascio S M. Novel strategies for immortalization of human hepatocytes.  Artif Organs. 2001;  25 529-538
    CrossrefPubMedGoogle Scholar
  • 42 Kulig K M, Vacanti J P. Hepatic tissue engineering.  Transpl Immunol. 2004;  12(3-4) 303-310
    CrossrefPubMedGoogle Scholar
  • 43 Okamura K, Asahina K, Fujimori H et al.. Generation of hybrid hepatocytes by cell fusion from monkey embryoid body cells in the injured mouse liver.  Histochem Cell Biol. 2006;  125 247-257
    CrossrefPubMedGoogle Scholar
  • 44 Tateno C, Yoshizane Y, Saito N et al.. Near completely humanized liver in mice shows human-type metabolic responses to drugs.  Am J Pathol. 2004;  165 901-912
    CrossrefPubMedGoogle Scholar
  • 45 Sandgren E P, Palmiter R D, Heckel J L et al.. Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene.  Cell. 1991;  66 245-256
    CrossrefPubMedGoogle Scholar
  • 46 Sandgren E P, Merlino G. Hepatocarcinogenesis in transgenic mice.  Prog Clin Biol Res. 1995;  391 213-222
    PubMedGoogle Scholar
  • 47 Rhim J A, Sandgren E P, Palmiter R D, Brinster R L. Complete reconstitution of mouse liver with xenogeneic hepatocytes.  Proc Natl Acad Sci U S A. 1995;  92 4942-4946
    PubMedGoogle Scholar
  • 48 Azuma H, Paulk N, Ranade A et al.. Robust expansion of human hepatocytes in Fah - / - /Rag2 - / - /Il2rg - / - mice.  Nat Biotechnol. 2007;  25 903-910
    CrossrefPubMedGoogle Scholar
  • 49 Grompe M, Lindstedt S, Al-Dhalimy M et al.. Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I.  Nat Genet. 1995;  10 453-460
    PubMedGoogle Scholar
  • 50 Overturf K, Al-Dhalimy M, Manning K, Ou C N, Finegold M, Grompe M. Ex vivo hepatic gene therapy of a mouse model of Hereditary Tyrosinemia Type I.  Hum Gene Ther. 1998;  9 295-304
    PubMedGoogle Scholar

Scott L NybergM.D. Ph.D. 

Professor of Surgery, Department of Surgery, Mayo Clinic

200 First Street SW, Rochester, MN 55905

Email: nyberg.scott@mayo.edu

      >